drugset / Trial / NCT01944293
Ketamine for Suicidality in Bipolar Depression
Phase 1/2
Completed
16 enrolled
New York State Psychiatric Institute
Brain & Behavior Research Foundation · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This study is designed to compare the effectiveness of two medications, Ketamine and Midazolam, for rapidly relieving suicidal thoughts in people suffering from bipolar depression. The first drug, ketamine, is an experimental antidepressant that early studies have shown may quickly reduce suicidal thoughts, but we are not sure how well it may work. Midazolam, the comparison drug, is not thought to reduce depression or suicidal thoughts.
Timeline
- Start
- 2013-09
- Primary completion
- 2017-09
- Completion
- 2018-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ketamine | Small molecule | 0.5 mg/kg | Intravenous |
| Comparator | Midazolam | Small molecule | 0.02 mg/kg | Intravenous |